Hint mode is switched on Switch off
For swift navigation between sections

Sanofi
LEI 549300E9PC51EN656011, SWIFT SAAVFRPPXXX

PDF download

Choose all Reset all
Download Cancel
Organization name
Sanofi SA
Country name
France
Country of registration
France
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
  • M/S&P/F
    *** / *** / ***
Public debt
20,960 mln USD

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients needs. Sanofi focuses on the field of healthcare with six growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets and animal health. Sanofi has a portfolio of prescription drugs, vaccines, generics and consumer healthcare products. In December 2011, Sanofi announced that it completed the divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International, Inc. The Company is active domestically and abroad, including other European countries, North and Latin Americas, Asia, Africa and Middle East. As of January 31, 2012, the Companys major shareholder was Loreal with a stake of 8.82%.

Awards

News

04/06/2026 Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
04/06/2026 Sanofi Launched 2026 Global Employee Stock Purchase Plan
01/06/2026 Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)
01/05/2026 New issues: Sanofi issued bonds (FR0014016SU0, FR0014016SW6, FR0014016SX4) in the amount of EUR 1000, EUR 650, EUR 650 mln maturing in 2029, 2033, 2037 respectively.
29/04/2026 Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%
All organization news

Documentation

IFRS/US GAAP reports

2025
II q eng
IV q eng
2024
II q eng
IV q eng
2023
II q eng
IV q eng
2022
II q eng
IV q eng
2021
II q eng
IV q eng
2020
II q eng
IV q eng
2019
II q eng
IV q eng
2018
II q eng
IV q eng
2017
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300E9PC51EN656011
  • SWIFT
    SAAVFRPPXXX
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • ICB
    4,500 Health Care
  • CIK
    0001121404
  • EIN
    13-3529324
  • SIREN
    395030844
Registration is required to get access.